Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
TG Therapeutics began the open-label, U.S. Phase IIb UNITY-DLBCL trial to evaluate oral TGR-1202 daily with or without IV ublituximab ( TG-1101) in about 200 patients. TG Therapeutics has exclusive, w...